title: The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet's disease.
abstract: OBJECTIVE
  The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor, (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.
  
  
  METHODS
  Sixty-five patients with BD and 21 healthy control subjects were included in the study, and serum angiogenin, bFGF, and VEGF concentrations were measured by using in-vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.
  
  
  RESULTS
  The median serum angiogenin level was significantly higher in patients with BD (391.8; range:151.6-594.8 pg/ml) than controls (298.8; range:241.9-449.6 pg/ml) (p = 0.001). The levels were similar in both ocular and non-ocular BD patients (p = 0.537). The mean serum bFGF level was higher in patients with BD (38.8 ± 12.3 pg/ml) than controls (33.2 ± 11.3 pg/ml); the median serum VEGF level was also higher in BD patients (239.7; range:53-991.3 pg/ml) than controls (189.4; range:53.6-357.9 pg/ml). But these differences were not statistically significant. Serum bFGF and VEGF levels were also not different statistically in ocular and non-ocular Behçet's patients. There was no statistically significant relationship between serum angiogenin, bFGF, and VEGF levels and the presence of active eye disease or anatomic location of uveitis. While there was a correlation of borderline significance in angiogenin levels between the patients with anterior uveitis and panuveitis (p = 0.053), we did not obtain any correlation between serum angiogenin, bFGF, and VEGF levels and the duration of BD.
  
  
  CONCLUSIONS
  This study suggests that angiogenin may be associated with pathophysiology of BD, and highlights the need of further investigation of the role of angiogenin, bFGF, and VEGF serum levels in BD susceptibility and its clinical manifestations.
authors.affiliation: Department of Clinical Biochemistry, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Yalçındağ
authors.forename: Yeşim
authors.initials: Y
authors.lastname: Gedik-Oğuz
authors.forename: F Nilüfer
authors.initials: FN
authors.lastname: Yalçındağ
mesh_terms: D000328:Adult; D000368:Aged; D001528:Behcet Syndrome / Q000097:blood* / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005128:Eye Diseases / Q000097:blood* / Q000503:physiopathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012259:Ribonuclease, Pancreatic / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D055815:Young Adult
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C046366:angiogenin; D012259:Ribonuclease, Pancreatic
references.citation: Rheumatol Int. 2005 Oct;25(8):599-603
references.pmid: 15257411
references.citation: Dig Dis Sci. 2004 Nov-Dec;49(11-12):1758-62
references.pmid: 15628698
references.citation: Iran J Kidney Dis. 2012 May;6(3):209-15
references.pmid: 22555486
references.citation: Fertil Steril. 2004 Jul;82(1):93-6
references.pmid: 15236995
references.citation: J Clin Pathol. 1996 Jun;49(6):508-10
references.pmid: 8763269
references.citation: Tissue Antigens. 2008 Dec;72(6):581-7
references.pmid: 19054372
references.citation: Thromb Res. 1984 May 15;34(4):277-85
references.pmid: 6429888
references.citation: Tohoku J Exp Med. 2010 Jun;221(2):119-23
references.pmid: 20484842
references.citation: Mol Biol Cell. 1998 Apr;9(4):875-84
references.pmid: 9529385
references.citation: Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1311-21
references.pmid: 8641834
references.citation: Oncogene. 2005 Jan 13;24(3):445-56
references.pmid: 15558023
references.citation: Am J Pathol. 1988 Feb;130(2):393-400
references.pmid: 3277442
references.citation: Postgrad Med J. 2000 Oct;76(900):629-37
references.pmid: 11009577
references.citation: Int J Dermatol. 2003 Oct;42(10):803-6
references.pmid: 14521694
references.citation: Am J Pathol. 1998 Aug;153(2):587-98
references.pmid: 9708818
references.citation: Nat Med. 2004 Oct;10(10):1041-2
references.pmid: 15459700
references.citation: J Thromb Haemost. 2006 Sep;4(9):1864-74
references.pmid: 16961595
references.citation: Cytokine. 1998 Apr;10(4):254-7
references.pmid: 9617569
references.citation: N Engl J Med. 1999 Oct 21;341(17):1284-91
references.pmid: 10528040
references.citation: J Invest Dermatol. 1995 Jul;105(1):44-50
references.pmid: 7615975
references.citation: Biochem Biophys Res Commun. 1993 Jul 30;194(2):799-803
references.pmid: 8343163
references.citation: Arthritis Rheum. 2004 Jul;50(7):2291-5
references.pmid: 15248229
references.citation: Ann Surg. 1992 Oct;216(4):401-6; discussion 406-8
references.pmid: 1417189
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: Br J Dermatol. 2007 Jan;156(1):32-7
references.pmid: 17199563
references.citation: Exp Mol Med. 2011 Apr 30;43(4):179-88
references.pmid: 21350328
references.citation: Int J Dermatol. 2003 Nov;42(11):870-5
references.pmid: 14636202
references.citation: Angiogenesis. 1999;3(3):189-99
references.pmid: 14517418
references.citation: Eur J Clin Invest. 2002 Feb;32(2):110-4
references.pmid: 11895457
references.citation: Head Face Med. 2010 Dec 22;6:29
references.pmid: 21176170
references.citation: Pathobiology. 1995;63(5):249-56
references.pmid: 8724206
references.citation: Clin Exp Med. 2004 Sep;4(1):10-20
references.pmid: 15598081
references.citation: Arthritis Rheum. 1999 Sep;42(9):1967-74
references.pmid: 10513814